← boothcheck

ABT vs EHC stock comparison

ABBOTT LABORATORIES vs Encompass Health Corporation. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

Where ABT and EHC diverge most: on implied growth (priced in), ABT reads +9.6% and EHC reads -3.5%; on fcf yield, ABT reads 4.5% and EHC reads -6.7%. The rest of the comparable metrics sit closer together. On valuation, today's ABT price has a different growth bar priced in than EHC (+9.6% implied for ABT vs -3.5% for EHC); the higher figure is the steeper assumption to clear, not a better or worse stock. What ABT's price implies is a bet that sits within the historical range (whole-company basis). What EHC's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.

ABT vs EHC: the numbers

MetricABTEHC
Price$93.93$110.11
Market cap$164.1B$11.1B
SectorDrug ManufacturersMedical Care
StageMatureMature
Implied growth (priced in)+9.6%-3.5%
P/E26.318.4
P/B3.113.35
P/S3.641.83
EV/EBITDA20.840.3
Revenue growth+6.6%+10.1%
Operating margin12.1%
Net margin13.9%10.0%
Return on equity11.9%18.4%
Return on assets5.7%8.3%
Return on invested capital6.6%
FCF yield4.5%-6.7%
Dividend yield2.6%0.7%
Debt / equity0.650.78
Current ratio1.391.17
Altman Z (solvency)7.162.54
Piotroski F (quality)6 / 95 / 9
Full ABT report → Full EHC report →
Get boothcheck's read on ABT and EHC, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.